Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year extension of study 2203 evaluating long-term safety and efficacy of balicatib (AAE581)
2004-002952-33Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Balicatib continuation arm with Placebo in year 1 then balicatib open label (2 arms). Primary endpoint: 3-year safety of AAE581 (balicatib). Started Feb 2005; status: terminated.
02
Drugs
balicatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2004-002952-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002952-33.